Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on CSL.
RELATED STOCKHEAD STORIES
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Experts
Scopo’s health powerplays: Get ready for the pullback
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
We’re still here: investors keen on health despite market shun
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
Health & Biotech
COVID-19 treatments are a better bet than a vaccine
Experts
ScoPo’s health powerplays: How to invest in COVID-19
Health & Biotech
Dr Boreham’s Crucible: Paradigm’s ‘ballsy’ move that landed it $35m after an FDA knock-back
Health & Biotech
Check up: Is anyone making non-COVID-19 money these days? Actually, yes
Health & Biotech
Your guide to COVID-19 vaccines: it’ll all be over soon
News
Planning to buy the dip? Read this first
News
The traps and the opportunities: How to play equity markets in a global pandemic
News
Could small caps and emerging companies boost our sovereign wealth fund?
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
Energy
Global glut great for Australia’s gas guzzling corporate guilds
News